Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02050269

Acronym

IoxRea

Enrollment

100

Registered

2014-01-30

Start date

2014-01-31

Completion date

2016-06-30

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Circulatory Failure

Brief summary

The objective of this study is to assess the feasibility of estimating the clearance of iohexol as an indirect measure of glomerular filtration rate in patients with unstable renal function in the intensive care unit through analysis of rich iohexol plasma kinetics.

Interventions

DRUGIohexol

Iohexol, 300 mg/mL

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Patient admitted to intensive care for less than 12 hours * Acute circulatory failure * Patient carrying an arterial catheter * Informed consent obtained * Affiliated to social security system

Exclusion criteria

* Administration of iohexol the week before intensive care admission * Administration of iohexol expected within 24 hours of study entry * Known history of cutaneous immediate or delayed allergic reaction to the injection of the product * Indication for albumin transfusion within 24 hours of potential inclusion in the study * Pregnancy or breastfeeding in progress * Patient under guardianship or judicial protection known at the time of inclusion * Withdrawal of consent * Administration of iohexol outside the study within 24 hours after administration of iohexol in the context of the study * Administration of intravenous albumin in the 24 hours following administration of iohexol in the context of the study

Design outcomes

Primary

Measure	Time frame
Plasma clearance of iohexol	24 hours

Secondary

Measure	Time frame
Plasma clearance of iohexol in patients developping or not acute kidney injury	7 days
Link between plasma iohexol clearance and kindney injury markers	24 hours
Link between injury and/or functional kidney dammage and subsequent acute kidney injury	7 days
Link between plasma iohexol clearance and urinary metabolomic markers	24 hours
Comparaison of plasma iohexol clearance measured with 3 and 6 vs. 9 kinetic points	24 hours

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026